Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
Impel NeuroPharma (NASDAQ: IMPL) announced that CEO Adrian Adams will participate in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Impel NeuroPharma (NASDAQ: IMPL) announced that CEO Adrian Adams will participate in two upcoming investor conferences. The Cowen & Co. 42nd Annual Health Care Conference will feature a fireside chat on March 7, 2022, at 1:30 p.m. ET, while the Oppenheimer 32nd Annual Healthcare Conference will include a company presentation on March 17, 2022, at 2:40 p.m. ET. Investors can access a live webcast and a 90-day replay on the company's website. Impel specializes in therapies for high unmet medical needs, focusing on the central nervous system.
Details
News Market Reaction – IMPL
The recorded move for IMPL in the trading session of this news was +11.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.
Cowen & Co. 42nd Annual Health Care Conference
Format: Fireside Chat
Date: Monday, March 7, 2022
Time: 1:30 p.m. ET
Oppenheimer 32nd Annual Healthcare Conference
Format: Company Presentation
Date: Thursday, March 17, 2022
Time: 2:40 p.m. ET
A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the website for 90 days.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Contact:
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.